Protease-Activated Receptor and Thrombomodulin Signaling in Blood Clotting and Cell Health
Official title: Protease Activated Receptor and Thrombomodulin Signaling by coagulation proteases
Funded at Oklahoma Medical Research Foundation · NIH-11377403 · Data updated 2026-11-12
This grant explores how thrombomodulin and related proteins control blood clotting and protect blood vessel cells, with findings that could influence treatments for clotting disorders and vascular inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma Medical Research Foundation NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | April 1, 2010 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $417,725 |
| NIH project number | 5R01HL101917-16 |
| Project ID | NIH-11377403 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals with vascular inflammation or clotting disorders where endothelial dysfunction is a concern, or patients undergoing studies related to thrombomodulin and coagulation signaling.
✕Less likely to help
People without vascular or coagulation issues may not directly benefit from this research.
What this research studies
The project focuses on how thrombomodulin on endothelial cells switches thrombin’s role from forming clots to preventing them, and how this interacts with protein C and receptors to support healthy blood vessels. It also investigates how the cytoplasmic part of thrombomodulin connects to the cell’s actin skeleton and signaling pathways, potentially shaping cell behavior. Researchers will probe how these interactions affect AMPK, mTOR signaling, and endothelial cell quiescence under different conditions. The work uses molecular and cellular approaches to map these pathways and their responses to thrombin and related proteins in human-relevant systems.
Why it matters
Potential benefit: Understanding these pathways could lead to new strategies to prevent excessive clotting and vascular inflammation, improving cardiovascular and inflammatory disease care.
How similar studies have gone: Previous findings support that TM and APC pathways influence endothelial signaling, though the exact links to PTEN/AKT/mTOR are still being clarified.
Where this research is happening
-
Oklahoma Medical Research Foundation
Oklahoma City, United States Active
Researchers
- Principal investigator: Xia, Lijun — Oklahoma Medical Research Foundation
- Study coordinator: Xia, Lijun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.